[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100603176":3},{"organization":4,"armGroups":7,"interventions":34,"overallOfficials":10,"centralContacts":39,"locations":49,"responsibleParty":66,"collaborators":10,"id":68,"slug":69,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":70,"sex":76,"minAge":10,"maxAge":10,"enrollmentInfo":77,"targetDuration":10,"studyType":80,"phases":10,"briefSummary":81,"conditions":82,"keywords":89,"overallStatus":52,"whyStopped":10,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},{"fullName":5,"class":6},"Hospices Civils de Lyon","OTHER",[8,14,18,22,26,30],{"label":9,"type":10,"description":11,"interventionNames":12},"group 1 : Patients with NMDAR encephalitis",null,"Patients with untreated anti-NMDAR encephalitis or with a decision to treat within the previous 30 days",[13],"Other: We aim to assess the clinical response to the treatment initiation protocols most commonly used in autoimmune encephalitis (first-line, first-line with rituximab, dual immunosuppression).",{"label":15,"type":10,"description":16,"interventionNames":17},"group 2 : Patients with GAD encephalitis","Patients with untreated anti-GAD encephalitis or with a decision to treat within the previous 30 days",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"group 3 : Patients with LGI1 encephalitis","Patients with untreated anti-LGI1 encephalitis or with a decision to treat within the previous 30 days",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"group 4 : Patients with IgLON5 encephalitis","Patients with untreated anti-IgLON5 encephalitis or with a decision to treat within the previous 30 days",[13],{"label":27,"type":10,"description":28,"interventionNames":29},"group 5 : Patients with GFAP encephalitis","Patients with untreated anti-GFAP encephalitis or with a decision to treat within the previous 30 days",[13],{"label":31,"type":10,"description":32,"interventionNames":33},"group 6 : Patients with CASPR2 encephalitis","Patients with untreated anti-CASPR2 encephalitis or with a decision to treat within the previous 30 days",[13],[35],{"type":6,"name":36,"description":37,"armGroupLabels":38,"otherNames":10},"We aim to assess the clinical response to the treatment initiation protocols most commonly used in autoimmune encephalitis (first-line, first-line with rituximab, dual immunosuppression).","The patients will be identified via the French Nationwide Multidisciplinary Team Meetings for Autoimmune encephalitis, which are conducted on a bi-monthly basis. All patients with newly diagnosed NMDAR, LGI1, CASPR2, IgLON5, GFAP or GAD65 encephalitis and treated for less than 8 weeks will be included. Treatment protocols at the initiation of therapy will be stratified into: 1) first-line only; 2) rituximab without cyclophosphamide; 3) rituximab combined with cyclophosphamide; 4) others.\n\nThe referral clinicians will be contacted by email and the data will be collected using standardized questionnaires, which will be sent at baseline (visit 1, V1) and 4 months after the initiation of therapy (visit 2, V2). The questionnaires will be structured into 7 sections:\n\n* 1 Demographics\n* 2 Symptoms\n* 3 Cognitive screening tests (MMSE, MoCA, and\u002For others)\n* 4 Level of dependence (ADL, I-ADL, mRS, CASE) and impact on social life\n* 5 Diagnostic tests (brain MRI, brain PET, CSF, and EEG findings)",[9,15,19,23,27,31],[40,45],{"name":41,"role":42,"phone":43,"phoneExt":10,"email":44},"Bastien Pr JOUBERT","CONTACT","04 78 86 17 89","bastien.joubert@chu-lyon.fr",{"name":46,"role":42,"phone":47,"phoneExt":10,"email":48},"Géraldine PICARD","04.72.35.58.42","geraldine.picard@chu-lyon.fr",[50],{"facility":51,"status":52,"city":53,"state":10,"zip":54,"country":55,"countryCode":56,"cosmosGeoPoint":57,"geoPoint":62,"contacts":63},"Hospices Civil de Lyon","RECRUITING","Bron","69677","France","FR",{"type":58,"coordinates":59},"Point",[60,61],4.91303,45.73865,{"lat":61,"lon":60},[64],{"name":65,"role":42,"phone":43,"phoneExt":10,"email":44},"Bastien JOUBERT, Professor",{"type":67,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100603176","medium-term-effects-of-treatments-in-autoimmune-encephalitis-100603176",false,"NCT07133113","Medium-term Effects of Treatments in Autoimmune Encephalitis","Medium-term Effects of Treatments in Autoimmune Encephalitis (META): a Real-life, Observational Prospective Study","META","Inclusion Criteria:\n\n* Adult or child patient with encephalitis defined as anti-GAD, NMDAR, LGI1, CASPR2, IgLON5 or GFAP\n* Untreated or with a decision to treat within the previous 30 days.\n\nExclusion Criteria:\n\n\\- Refusal by the referring doctor to participate or refusal by the patient mentioned in the objection to the use of his\u002Fher clinical data.","ALL",{"count":78,"type":79},200,"ESTIMATED","OBSERVATIONAL","Autoimmune encephalitides are severe neurological disorders requiring urgent treatment, even though there is no standard guideline by lack of empirical evidence. Commonly used treatments are divided into so-called first-line (steroids, intravenous immunoglobulins, plasma exchanges) and second-line (rituximab, cyclophosphamide, tocilizumab, others), and may be used in association or sequentially. There is no standard practice, and initial treatment protocol may consist in first-line alone, first-line with rituximab, or first-line with dual immunosuppression (rituximab and cyclophosphamide). Absence of clear response to initial treatment in the first 4 to 6 weeks may indicate undertreatment and is generally followed by treatment escalation, mostly to dual immunosuppression. However, as the frequency of non-responders to initial treatment is unknown, it is still unclear whether dual immunosuppression should be offered to all patients from inception.",[83,84,85,86,87,88],"NMDAR Autoimmune Encephalitis","LGI1 Antibody Associated Encephalitis","CASPR2-Antibody","IgLON5","GAD65","GFAP",[90,91],"Paraneoplastic neurological disorder","autoimmune encephalitis","2025-08-13",{"date":94,"type":95},"2025-08-20","ACTUAL",{"date":97,"type":95},"2024-09-01",{"date":99,"type":79},"2027-03-01",{"name":5,"class":6},1]